Discovery of Novel Epigenetic Marks in Mammalian Cells (R21)

The summary for the Discovery of Novel Epigenetic Marks in Mammalian Cells (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Discovery of Novel Epigenetic Marks in Mammalian Cells (R21): -Purpose. The National Institutes of Health invites applications that propose to discover novel pathways of stable, differential silencing and activation of gene expression in eukaryotic organisms that may be applicable to human disease pathogenesis. A companion announcement using the R01 mechanism (RFA-RM-07-015), is focused on establishment and validation of epigenetic marks in mammalian cells. In the long term, advances in these areas will enhance our ability to investigate, diagnose and ameliorate human disease with a significant epigenetic component. -Mechanism of Support.The R21 Exploratory/Developmental Grant mechanism will be used for this FOA, which runs in parallel with RFA-RM-07-015 that solicits applications using the R01 mechanism. -Funds Available and Anticipated Number of Awards.

Federal Grant Title:	Discovery of Novel Epigenetic Marks in Mammalian Cells (R21)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-RM-07-016
Type of Funding:	Grant
CFDA Numbers:	93.310
CFDA Descriptions:	Trans-NIH Research Support
Current Application Deadline:	No deadline provided
Original Application Deadline:	Feb 14, 2008
Posted Date:	Nov 16, 2007
Creation Date:	Nov 16, 2007
Archive Date:	Mar 16, 2008
Total Program Funding:	$3,500,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: County governments Small businesses Private institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Special district governments State governments Others (see text field entitled "Additional Information on Eligibility" for clarification) Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Independent school districts
Additional Information on Eligibility: Foreign institutions are eligible to apply.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial No...; • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...; • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional); • NIH Directors Early Independence Awards (DP5 Clinical Trial Optional); • NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional); • Using Metabolomics to Investigate Biological Pathways and Networks (R01); • Assay Development for High Throughput Molecular Screening (R21); • Membrane Protein Production and Structure Determination (R01)
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...